140 related articles for article (PubMed ID: 35511740)
1. Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors.
Scribner JA; Hicks SW; Sinkevicius KW; Yoder NC; Diedrich G; Brown JG; Lucas J; Fuller ME; Son T; Dastur A; Hooley J; Espelin C; Themeles M; Chen FZ; Li Y; Chiechi M; Lee J; Barat B; Widjaja L; Gorlatov S; Tamura J; Ciccarone V; Ab O; McEachem KA; Koenig S; Westin EH; Moore PA; Chittenden T; Gregory RJ; Bonvini E; Loo D
Mol Cancer Ther; 2022 Jul; 21(7):1047-1059. PubMed ID: 35511740
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer.
Scribner JA; Brown JG; Son T; Chiechi M; Li P; Sharma S; Li H; De Costa A; Li Y; Chen Y; Easton A; Yee-Toy NC; Chen FZ; Gorlatov S; Barat B; Huang L; Wolff CR; Hooley J; Hotaling TE; Gaynutdinov T; Ciccarone V; Tamura J; Koenig S; Moore PA; Bonvini E; Loo D
Mol Cancer Ther; 2020 Nov; 19(11):2235-2244. PubMed ID: 32967924
[TBL] [Abstract][Full Text] [Related]
3. DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors.
Li X; Yao J; Qu C; Luo L; Li B; Zhang Y; Zhu Z; Qiu Y; Hua H
J Transl Med; 2024 Apr; 22(1):362. PubMed ID: 38632563
[TBL] [Abstract][Full Text] [Related]
4. IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.
Ab O; Whiteman KR; Bartle LM; Sun X; Singh R; Tavares D; LaBelle A; Payne G; Lutz RJ; Pinkas J; Goldmacher VS; Chittenden T; Lambert JM
Mol Cancer Ther; 2015 Jul; 14(7):1605-13. PubMed ID: 25904506
[TBL] [Abstract][Full Text] [Related]
5. The effect of disintegrin-metalloproteinase ADAM9 in gastric cancer progression.
Kim JM; Jeung HC; Rha SY; Yu EJ; Kim TS; Shin YK; Zhang X; Park KH; Park SW; Chung HC; Powis G
Mol Cancer Ther; 2014 Dec; 13(12):3074-85. PubMed ID: 25344581
[TBL] [Abstract][Full Text] [Related]
6. SGN-CD228A Is an Investigational CD228-Directed Antibody-Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models.
Mazahreh R; Mason ML; Gosink JJ; Olson DJ; Thurman R; Hale C; Westendorf L; Pires TA; Leiske CI; Carlson M; Nguyen LT; Cochran JH; Okeley NM; Yumul R; Jin S; Stone IJ; Sahetya D; Nesterova A; Allred S; Hensley KM; Hu R; Lawrence R; Lewis TS; Sandall S
Mol Cancer Ther; 2023 Apr; 22(4):421-434. PubMed ID: 36800443
[TBL] [Abstract][Full Text] [Related]
7. MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors.
Merlino G; Fiascarelli A; Bigioni M; Bressan A; Carrisi C; Bellarosa D; Salerno M; Bugianesi R; Manno R; Bernadó Morales C; Arribas J; Dusek RL; Ackroyd JE; Pham PH; Awdew R; Aud D; Trang M; Lynch CM; Terrett J; Wilson KE; Rohlff C; Manzini S; Pellacani A; Binaschi M
Mol Cancer Ther; 2019 Sep; 18(9):1533-1543. PubMed ID: 31227646
[TBL] [Abstract][Full Text] [Related]
8. ASN004, A 5T4-targeting scFv-Fc Antibody-Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models.
Smith RA; Zammit DJ; Damle NK; Usansky H; Reddy SP; Lin JH; Mistry M; Rao NS; Denis LJ; Gupta S
Mol Cancer Ther; 2021 Aug; 20(8):1327-1337. PubMed ID: 34045226
[TBL] [Abstract][Full Text] [Related]
9. A novel antibody-drug conjugate, HcHAb18-DM1, has potent anti-tumor activity against human non-small cell lung cancer.
Huhe M; Lou J; Zhu Y; Zhao Y; Shi Y; Wang B; Sun X; Zhang X; Zhang Y; Chen ZN
Biochem Biophys Res Commun; 2019 Jun; 513(4):1083-1091. PubMed ID: 31010682
[TBL] [Abstract][Full Text] [Related]
10. A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody-Drug Conjugate for Targeting Melanoma.
Shi J; Jiao T; Guo Q; Weng W; Ma L; Zhang Q; Wang L; Zhang J; Chen C; Huang Y; Wang M; Pan R; Tang Y; Hu W; Meng T; Liu SH; Guo J; Kong Y; Meng X
Cancer Res; 2023 Nov; 83(22):3783-3795. PubMed ID: 37668527
[TBL] [Abstract][Full Text] [Related]
11. Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect.
Golfier S; Kopitz C; Kahnert A; Heisler I; Schatz CA; Stelte-Ludwig B; Mayer-Bartschmid A; Unterschemmann K; Bruder S; Linden L; Harrenga A; Hauff P; Scholle FD; Müller-Tiemann B; Kreft B; Ziegelbauer K
Mol Cancer Ther; 2014 Jun; 13(6):1537-48. PubMed ID: 24714131
[TBL] [Abstract][Full Text] [Related]
12. Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation.
Hong EE; Erickson H; Lutz RJ; Whiteman KR; Jones G; Kovtun Y; Blanc V; Lambert JM
Mol Pharm; 2015 Jun; 12(6):1703-16. PubMed ID: 25856201
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Activity of SAR408701: A Novel Anti-CEACAM5-maytansinoid Antibody-drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors.
Decary S; Berne PF; Nicolazzi C; Lefebvre AM; Dabdoubi T; Cameron B; Rival P; Devaud C; Prades C; Bouchard H; Cassé A; Henry C; Amara C; Brillac C; Ferrari P; Maçon L; Lacoste E; Combeau C; Beys E; Naimi S; García-Echeverría C; Mayaux JF; Blanc V
Clin Cancer Res; 2020 Dec; 26(24):6589-6599. PubMed ID: 33046521
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Antitumor Activity of a Novel Anti-c-KIT Antibody-Drug Conjugate against Mutant and Wild-type c-KIT-Positive Solid Tumors.
Abrams T; Connor A; Fanton C; Cohen SB; Huber T; Miller K; Hong EE; Niu X; Kline J; Ison-Dugenny M; Harris S; Walker D; Krauser K; Galimi F; Wang Z; Ghoddusi M; Mansfield K; Lee-Hoeflich ST; Holash J; Pryer N; Kluwe W; Ettenberg SA; Sellers WR; Lees E; Kwon P; Abraham JA; Schleyer SC
Clin Cancer Res; 2018 Sep; 24(17):4297-4308. PubMed ID: 29764854
[No Abstract] [Full Text] [Related]
15. TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors.
Gymnopoulos M; Betancourt O; Blot V; Fujita R; Galvan D; Lieuw V; Nguyen S; Snedden J; Stewart C; Villicana J; Wojciak J; Wong E; Pardo R; Patel N; D'Hooge F; Vijayakrishnan B; Barry C; Hartley JA; Howard PW; Newman R; Coronella J
Mol Oncol; 2020 Jan; 14(1):54-68. PubMed ID: 31736230
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for Treatment of Nectin-4-expressing Cancers.
Zhou W; Fang P; Yu D; Ren H; You M; Yin L; Mei F; Zhu H; Wang Z; Xu H; Cao Y; Sun X; Xu X; Bi J; Wang J; Ma L; Wang X; Chen L; Zhang Y; Cen X; Zhu X; Lou L; Liu D; Tan X; Yang J; Meng T; Shen J
Mol Cancer Ther; 2023 Aug; 22(8):913-925. PubMed ID: 37196158
[TBL] [Abstract][Full Text] [Related]
17. A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma.
Munekage E; Serada S; Tsujii S; Yokota K; Kiuchi K; Tominaga K; Fujimoto M; Kanda M; Uemura S; Namikawa T; Nomura T; Murakami I; Hanazaki K; Naka T
Neoplasia; 2021 Sep; 23(9):939-950. PubMed ID: 34332450
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH
J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619
[TBL] [Abstract][Full Text] [Related]
19. Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-Drug Conjugate for Treatment of CLDN18.2-Positive Cancers.
O'Brien NA; McDermott MSJ; Zhang J; Gong KW; Lu M; Hoffstrom B; Luo T; Ayala R; Chau K; Liang M; Madrid AM; Donahue TR; Glaspy JA; Presta L; Slamon DJ
Mol Cancer Ther; 2023 Dec; 22(12):1365-1375. PubMed ID: 37788341
[TBL] [Abstract][Full Text] [Related]
20. Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers.
Li X; Zhou S; Abrahams CL; Krimm S; Smith J; Bajjuri K; Stephenson HT; Henningsen R; Hanson J; Heibeck TH; Calarese D; Tran C; Yin G; Stafford RL; Yam AY; Kline T; De Almeida VI; Sato AK; Lupher M; Bedard K; Hallam TJ
Mol Cancer Ther; 2023 Feb; 22(2):155-167. PubMed ID: 36459691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
